Literature DB >> 9601040

Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continuous assay and inhibition by tripeptide aldehydes and clasto-lactacystin beta-lactone.

T A McCormack1, A A Cruikshank, L Grenier, F D Melandri, S L Nunes, L Plamondon, R L Stein, L R Dick.   

Abstract

We have developed an assay to continuously monitor the branched amino acid preferring peptidase (BrAAP) activity of the proteasome. This assay is based on the hydrolysis of the fluorogenic peptide, Abz-Gly-Pro-Ala-Leu-Ala-Nba (Abz is 2-aminobenzoyl and Nba is 4-nitrobenzylamide) which is cleaved exclusively at the Leu-Ala bond by the 20S proteasome with a kc/Km value of 13 000 M-1 s-1. Hydrolysis of this peptide is accompanied by an increase in fluorescence intensity (lambda ex = 340 nm, lambda em = 415 nm) due to release of the internally quenched 2-aminobenzoyl fluorescence that accompanies diffusion apart of the hydrolysis products, Abz-Gly-Pro-Ala-Leu and Ala-Nba. Using this assay, we examined inhibition of the BrAAP activity of the proteasome by a series of tripeptide aldehydes, Z-Leu-Leu-Xaa-H. When Xaa = Phe, (p-Cl)Phe, and Trp we observe biphasic or partial inhibition of the BrAAP activity. In contrast, when Xaa = Nva and Leu, simple inhibition kinetics are observed and allow us to calculate Ki values of 120 nM and 12 nM, respectively. The inhibitors that exhibit simple inhibition kinetics for BrAAP activity are also approximately equipotent for inhibition of the chymotrypsin-like (ChT-L) and peptidyl-glutamyl peptide hydrolyzing (PGPH) activities, dissociation constants varying by less than 25-fold, whereas the inhibitors that exhibit biphasic inhibition kinetics for BrAAP activity are >300-fold more potent for inhibiting ChT-L activity than for PGPH activity. Inactivation of the BrAAP activity of the proteasome by clasto-lactacystin beta-lactone is also biphasic. beta-Lactone inactivates approximately 60% of the BrAAP activity rapidly, with kinetics indistinguishable from its inactivation of the chymotrypsin-like activity. The remaining 40% of the BrAAP activity is inactivated by beta-lactone at a 50-fold slower rate, with kinetics indistinguishable from its inactivation of the PGPH activity. These results suggest a mechanism in which hydrolysis of Abz-Gly-Pro-Ala-Leu-Ala-Nba (i.e., BrAAP activity) occurs at two different active sites in the 20S proteasome, and that these two active sites are the same ones that catalyze the previously described ChT-L and PGPH activities.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9601040     DOI: 10.1021/bi980097q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

Review 1.  Structure and functions of arthropod proteasomes.

Authors:  D L Mykles
Journal:  Mol Biol Rep       Date:  1999-04       Impact factor: 2.316

Review 2.  The ubiquitin-proteasome pathway and proteasome inhibitors.

Authors:  J Myung; K B Kim; C M Crews
Journal:  Med Res Rev       Date:  2001-07       Impact factor: 12.944

3.  Antitrypanosomal activities of proteasome inhibitors.

Authors:  Njinkeng Joseph Nkemngu; Joseph Nkemgu-Njinkeng; Vera Rosenkranz; Michael Wink; Dietmar Steverding
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Endoplasmic reticulum stress-induced cell death mediated by the proteasome.

Authors:  L Egger; D T Madden; C Rhême; R V Rao; D E Bredesen
Journal:  Cell Death Differ       Date:  2007-03-30       Impact factor: 15.828

5.  Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting β1 subunit expression and disrupting proteasome assembly.

Authors:  Peng Sun; Li-Xing Feng; Dong-Mei Zhang; Miao Liu; Wang Liu; Tian Mi; Wan-Ying Wu; Bao-Hong Jiang; Min Yang; Li-Hong Hu; De-An Guo; Xuan Liu
Journal:  Acta Pharmacol Sin       Date:  2016-05-30       Impact factor: 6.150

6.  Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib.

Authors:  Anne C Mirabella; Alexandre A Pletnev; Sondra L Downey; Bogdan I Florea; Tamer B Shabaneh; Matthew Britton; Martijn Verdoes; Dmitri V Filippov; Herman S Overkleeft; Alexei F Kisselev
Journal:  Chem Biol       Date:  2011-05-27

7.  Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasomes in cultured cells.

Authors:  R C Gardner; S J Assinder; G Christie; G G Mason; R Markwell; H Wadsworth; M McLaughlin; R King; M C Chabot-Fletcher; J J Breton; D Allsop; A J Rivett
Journal:  Biochem J       Date:  2000-03-01       Impact factor: 3.857

8.  Fellutamide B is a potent inhibitor of the Mycobacterium tuberculosis proteasome.

Authors:  Gang Lin; Dongyang Li; Tamutenda Chidawanyika; Carl Nathan; Huilin Li
Journal:  Arch Biochem Biophys       Date:  2010-06-15       Impact factor: 4.013

9.  Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

Authors:  Michael Frezza; Sarmad Sahiel Hindo; Dajena Tomco; Marco M Allard; Qiuzhi Cindy Cui; Mary Jane Heeg; Di Chen; Q Ping Dou; Cláudio N Verani
Journal:  Inorg Chem       Date:  2009-07-06       Impact factor: 5.165

10.  Peptide and Peptide-Like Modulators of 20S Proteasome Enzymatic Activity in Cancer Cells.

Authors:  Carlos García-Echeverría
Journal:  Int J Pept Res Ther       Date:  2006-03-04       Impact factor: 1.931

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.